Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.
How this was made
The 30-second read
Why it matters
The failure removes a potential new revenue stream and may shift investor focus to the cGVHD program.
Market read
The trial miss drives a sharp sell‑off in SNDX and could influence sentiment toward similar fibrosis programs.
What to watch
The safety profile was clean and the cGVHD studies continue, which could mitigate the negative sentiment over time.
Background
Syndax's axatilimab is already FDA‑approved for chronic graft‑versus‑host disease; the company halted its IPF development after the Phase II miss.
Ticker impact
Syndax reported its Phase II IPF study failed to meet the primary endpoint, causing a 15.7% share drop.
likely further decline as the market prices in the failed study and halts IPF development
Clinical trial failures for biotech firms typically trigger sustained sell‑offs, especially when the program is discontinued.
Market effects
May weigh on other biotech stocks with IPF pipelines and raise caution on mid‑stage fibrosis trials.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond the niche biotech community.
Counterpoint
If the cGVHD program shows strong data, the stock could rebound on the remaining pipeline potential.
Key entities
- companySyndax Pharmaceuticals
Biotech firm developing axatilimab.